Chong Kun Dang Pharmaceutical Corp
KRX:185750
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Chong Kun Dang Pharmaceutical Corp
Depreciation & Amortization
Chong Kun Dang Pharmaceutical Corp
Depreciation & Amortization Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Depreciation & Amortization | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Chong Kun Dang Pharmaceutical Corp
KRX:185750
|
Depreciation & Amortization
-₩9.3B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-10%
|
|
|
Yuhan Corp
KRX:000100
|
Depreciation & Amortization
-₩30.5B
|
CAGR 3-Years
-49%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-28%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Depreciation & Amortization
-₩16.8B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Depreciation & Amortization
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Depreciation & Amortization
-₩3.7B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-29%
|
|
|
C
|
Caregen Co Ltd
KOSDAQ:214370
|
Depreciation & Amortization
-₩2.4B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
Chong Kun Dang Pharmaceutical Corp
Glance View
Chong Kun Dang Pharmaceutical Corp. engages in the manufacture, distribution, research, and development of pharmaceuticals. The company is headquartered in Seoul, Seoul. The company went IPO on 2013-12-06. The firm is mainly involved in the production and sale of prescription drugs such as antidiabetic treatments, cerebrovascular disease treatments, hypertension treatments and hyperlipidemia therapies. In addition, the Company provides over the counter (OTC) drugs including penzal, prefermine and modcol; quasi-drugs including insecticides and hair dyes; and health functional food. The firm sells products in domestic and overseas markets.
See Also
What is Chong Kun Dang Pharmaceutical Corp's Depreciation & Amortization?
Depreciation & Amortization
-9.3B
KRW
Based on the financial report for Dec 31, 2025, Chong Kun Dang Pharmaceutical Corp's Depreciation & Amortization amounts to -9.3B KRW.
What is Chong Kun Dang Pharmaceutical Corp's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 10Y
-10%
Over the last year, the Depreciation & Amortization growth was -13%. The average annual Depreciation & Amortization growth rates for Chong Kun Dang Pharmaceutical Corp have been -15% over the past three years , -12% over the past five years , and -10% over the past ten years .
